Study of Symptoms Linked to Covid-19 in Residents and Professionals in EHPAD, Associated With a Dual Diagnostic Approach by PCR and Serology: a Cohort in Île-de-France.
NCT ID: NCT04677283
Last Updated: 2023-02-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1059 participants
OBSERVATIONAL
2020-05-07
2021-07-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER
NCT04341142
Post-Covid Condition Cohort: Evolution of Symptomatology, Patient Profile and Associated Prognostic Factors
NCT05610436
Caracterisation of COVID-19 Patients Hospitalized in Infectious Disease Department
NCT04779021
Developement and Evaluation of Serological Assays for COVID-19
NCT04377763
Health Professional Exposure Assessment to Covid-19
NCT04429724
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
At the initiative of the ARS Ile-de-France, residents and professionals of selected EHPADs will be subjected to systematic screening by RT-PCR for Covid-19, then by serology after the first screening, regardless of whether either the result
Samples, by nasopharyngeal swab for RT-PCR, by capillary blood sampling or venipuncture according to the technique for serology, will be carried out according to the doctrines issued by the ARS Ile de France and the variations proposed by the appropriate departmental directorates in depending on local resources. The results will be brought to the attention of EHPADs to adapt the care of residents and positive professionals.
Data will be collected daily from collection for the first test (RT-PCR), or retrospectively if the collection took place before the study.
Regarding the approach for collecting serologies:
* All subjects included with a negative PCR will be offered the serological test, in accordance with the recommendations in force or the medical decisions of the establishments.
* The qualitative results of the serologies of the subjects included in the study (residents and professionals) will be collected according to the same circuit as those of the RT-PCRs.
* Only the symptoms of residents with a positive serology will be collected, from the date of the sample and for a period of 14 days.
* The symptoms of professionals with a positive serology can be collected, from the date of the sample and for a period of 14 days without mandatory character.
* Both techniques (ELISA or TROD) are accepted and the serology values will not be collected.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. / Professionals in nursing homes in Île-de-France in which systematic screening tests for Covid-19 were carried out and agreeing to participate in the study: nursing assistants, nurses, coordinating doctors, hotel and service agents hygiene, etc.
Exclusion Criteria
2. / Subjects who have not had a diagnostic test by RT-PCR.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gérond'if
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martine LE NOC - SOUDANI, MD
Role: STUDY_CHAIR
Autonomy Department; ARS Île-de-France
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Autonomy Department; ARS Île-de-France
Paris, ARS Île-de-France, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-A01027-32
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.